Last Seven Days

29 articles from the last seven days

• 
  Matt Zeller launches new Australian pharma

  Five months after leaving Arrotex, the former Novartis Country President ANZ is launching his own Sydney-headquartered pharma company with another high-profile exec as Co-Founder

  6 Nov 2026
• 
  Pharma sells off Aussie business

  This company will now be a specialty pharma focused on the United States with its Australian assets moving to new hands for $55M

  6 Nov 2026
• 
  Pfizer names permanent ANZ leader

  He knows plenty about the role, having served as interim Managing Director for six months, now this leader has officially landed the top job, providing certainty for the pharma as it navigates a changing reimbursement landscape

  6 Nov 2026
• 
  Drugs dropped from PBAC meeting

  Three drugs were removed and another added in a last-minute revision to the agenda for the PBAC's last three-day meeting for 2026

  6 Nov 2026
• 
  Country boss adds new leadership hat

  AstraZeneca leader joins board to promote trade between Europe and Australia bolstering collaboration, innovation and investment

  6 Nov 2026
• 
  Omico names genomic profiling partners

  Four organisations have been selected to provide comprehensive genomic profiling for 25,000 Australians in the next phase of this screening program

  6 Nov 2026
• 
  What doctors really want Reps to talk about

  More than four in 10 clinicians say conversations with reps are mostly about products but what they'd really like to discuss is this...

  6 Nov 2026
• 
  Pharma signs its biggest ever milestones deal

  Mega license agreement inked with Chinese powerhouse covering six antibody-drug conjugate and T-cell engager programs

  6 Nov 2026
• 
  Blue wave to break against MFN

  The MFN isn't going anywhere soon, and the Commonwealth will need to adjust its pricing expectations if it wants Australians to gain access to the latest medicines

  5 Nov 2026
• 
  One webpage, 11 Code Breaches

  The hardline UK industry watchdog is at it again, slapping a company with 11 breaches of the Code over a single webpage on a Congress website after a complaint from an ex-employee which described the company's missteps as an embarrassment to the industry

  5 Nov 2026
• 
  Drug fails four months after $2.2B upfront buy

  Potential first-in-class treatment for a disease with high unmet need falls at the finish line of a pivotal trial after this pharma paid a hefty price in July

  5 Nov 2026
• 
  What drugs are on MS patients' Wish List?

  While RRMS is a PBS success story with Australians having the best access to meds in the world, there are new drugs coming that also need to be funded

  5 Nov 2026
• 
  11 drugs join TGA review list

  An update to the TGA's prescription medicines under evaluation list shows 11 drug applications were accepted in August, signalling what could enter the Australian market next year

  5 Nov 2026
• 
  Pharmac says no to weight loss funding

  The decision came despite a high-priority recommendation from its Advisory Group with the current fiscal environment and constraints of the public health system to blame

  4 Nov 2026
• 
  Aussie race to market kicks off for obesity pills

  The first oral GLP-1 drug has been approved for use in Australia for weight loss and will likely hit the private market this year, with a rival hot on its heels

  4 Nov 2026
• 
  Who's opening its doors in the US?

  Just months after undergoing a major rebrand, this Australian biotech is embarking on its next phase of growth, with plans to establish a US subsidiary

  4 Nov 2026
• 
  Aussies tapped for regional roles

  In the latest round of job moves, industry leaders move up alongside long-timers changing companies - one after almost 30 years working at the same pharma

  4 Nov 2026
• 
  Can pharma sustain the blockbuster boom?

  The number of blockbuster drugs have skyrocketed, with a new report taking a deep dive into whether industry can sustain the boom in the face of looming patent cliffs

  4 Nov 2026
• 
  Meet the Best Drugs of 2026

  A drug currently seeking to unlock broader government subsidy in Australia was crowned one of the best products of 2026 at the Prix Galien USA awards

  3 Nov 2026
• 
  Aussies find new combo to tackle deadly cancer

  After this drug wowed ESMO last month Australian researchers have discovered another combo that could disrupt treatment for small cell lung cancer

  3 Nov 2026